文献速递眼底病与葡萄膜炎

KIF13B介导的VEGFR2转运作为湿性年龄相关性黄斑变性的新治疗靶点

VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2021-01-01

本研究开发了可局部滴眼的肽KAI,选择性干扰VEGFR2向细胞表面转运,以阻断VEGF信号。在小鼠激光诱导CNV模型中,KAI滴眼液显著减少CNV进展,效果与抗VEGF玻璃体腔注射相当。KIF13B基因缺失证实该转运蛋白在湿性AMD新生血管中的关键作用。

要点

  • KAI肽滴眼液可成功递送至小鼠眼后段并特异性结合VEGFR2。
  • KAI滴眼液在激光诱导CNV模型中显著减少疾病进展,效果与抗VEGF注射相当。
  • KIF13B基因缺失证实VEGFR2转运在湿性AMD新生血管中的关键作用。

核心结论

  • 药理学抑制与遗传学缺失互补证明靶向VEGFR2转运可抑制湿性AMD病理性血管生成。

研究设计与样本

  • 临床前动物实验:使用小鼠激光诱导CNV模型,比较KAI滴眼液与对照肽及抗VEGF或IgG玻璃体腔注射。

主要发现

  • 表面等离子共振证实KAI对VEGFR2具有特异性和高亲和力。
  • 冷冻切片和ELISA显示KAI滴眼液可递送至小鼠眼后段。
  • KAI滴眼液显著减少激光诱导CNV的疾病进展。
  • 与当前疗法比较,KAI滴眼液预防湿性AMD CNV效果与当前疗法相当。
  • KIF13B基因缺失证实其在湿性AMD疾病进展和脉络膜血管新生中的关键作用。

临床怎么用

  • KAI滴眼液作为局部给药方式,可能为湿性AMD提供替代抗VEGF玻璃体腔注射的潜在治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vascular endothelial growth factor (VEGF) and its receptor VEGFR2 are promising therapeutic targets for wet age-related macular degeneration (AMD). As a topically applicable option, we developed the peptide KAI to selectively interfere with VEGFR2 trafficking to the cell surface where it receives VEGF. This study sought to determine the efficacy of KAI in the mouse model of choroidal neovascularization (CNV). METHODS: The specificity of KAI was tested by surface plasmon resonance. The drug delivery was analyzed by cryosection and the ELISA after treatment of KAI eyedrop to the mouse eyes. For the laser-induced CNV model, mice with laser-induced ruptures in Bruch's membrane received daily treatment of KAI eyedrop or control peptide. The other groups of mice received intravitreal injection of anti-VEGF or IgG control. After two weeks, CNV was quantified and compared. RESULTS: First, we showed the specificity and high affinity of KAI to VEGFR2. Next, biodistribution revealed successful delivery of KAI eyedrop to the back of the mouse eyes. KAI significantly reduced the disease progression in laser-induced CNV. The comparison with current therapy suggests that KAI eyedrop is as effective as current therapy to prevent CNV in wet AMD. Moreover, the genetic deletion of a kinesin KIF13B, which mediates VEGFR2 trafficking to the cell surface, confirmed the pivotal role of KIF13B in disease progression of wet AMD and neovascularization from choroidal vessels. CONCLUSIONS: Taken together, pharmacologic inhibition and genetic deletion complementarily suggest the therapeutic possibility of targeting VEGFR2 trafficking to inhibit pathological angiogenesis in wet AMD.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Waters SB, Zhou C, Nguyen T, et al. VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2021. PMID: 33533881. doi:10.1167/iovs.62.2.5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。